Moomoo AI 已提取核心訊息
On January 18, 2024, NexImmune, Inc. held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting did not reach a quorum as per the company's Amended and Restated Bylaws, with only 331,696 shares represented. Consequently, the meeting was adjourned without conducting any business, to allow more time for stockholders to vote and to achieve the required quorum. The adjourned meeting is scheduled to reconvene virtually on February 7, 2024. The record date for stockholder determination remains November 6, 2023, and those who have already voted do not need to take further action. The company's definitive proxy statement was filed with the SEC on November 20, 2023, and no changes have been made to the proposals since. NexImmune is...Show More
On January 18, 2024, NexImmune, Inc. held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting did not reach a quorum as per the company's Amended and Restated Bylaws, with only 331,696 shares represented. Consequently, the meeting was adjourned without conducting any business, to allow more time for stockholders to vote and to achieve the required quorum. The adjourned meeting is scheduled to reconvene virtually on February 7, 2024. The record date for stockholder determination remains November 6, 2023, and those who have already voted do not need to take further action. The company's definitive proxy statement was filed with the SEC on November 20, 2023, and no changes have been made to the proposals since. NexImmune is actively soliciting votes and encourages stockholders to review the proxy statement and vote if they have not already done so. The company also announced that its current cash and cash equivalents are expected to sustain operations through mid-February 2024 and it continues to explore strategic or financing alternatives. As of the record date, NexImmune had 1,058,125 shares of common stock issued and outstanding.
2024年1月18日，NexImmune, Inc.舉行了一次股東特別會議，就該公司的清算和解散進行投票。但是，根據公司經修訂和重述的章程，會議沒有達到法定人數，僅有331,696股股票。因此，會議在沒有進行任何事務的情況下休會，以便讓股東有更多時間進行投票並達到所需的法定人數。休會後的會議計劃於2024年2月7日虛擬地重新召開。股東決定的記錄日期仍然是2023年11月6日，已經投票的人無需採取進一步行動。該公司的最終委託書已於2023年11月20日向美國證券交易委員會提交，此後沒有對提案進行任何修改。NexImmune正在積極徵集選票，並鼓勵股東審查委託書，如果尚未這樣做，則進行投票。該公司還宣佈，其目前的現金和現金等價物預計將持續運營至2024年2月中旬，並將繼續探索戰略或融資替代方案。截至創紀錄的日期，NexImmune已發行和流通了1,058,125股普通股。
2024年1月18日，NexImmune, Inc.舉行了一次股東特別會議，就該公司的清算和解散進行投票。但是，根據公司經修訂和重述的章程，會議沒有達到法定人數，僅有331,696股股票。因此，會議在沒有進行任何事務的情況下休會，以便讓股東有更多時間進行投票並達到所需的法定人數。休會後的會議計劃於2024年2月7日虛擬地重新召開。股東決定的記錄日期仍然是2023年11月6日，已經投票的人無需採取進一步行動。該公司的最終委託書已於2023年11月20日向美國證券交易委員會提交，此後沒有對提案進行任何修改。NexImmune正在積極徵集選票，並鼓勵股東審查委託書，如果尚未這樣做，則進行投票。該公司還宣佈，其目前的現金和現金等價物預計將持續運營至2024年2月中旬，並將繼續探索戰略或融資替代方案。截至創紀錄的日期，NexImmune已發行和流通了1,058,125股普通股。
有用
沒用